Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 7.02 1.59% 0.11
ALNA closed up 1.59 percent on Tuesday, February 19, 2019, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ALNA trend table...

Date Alert Name Type % Chg
Feb 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 19 Narrow Range Bar Range Contraction 0.00%
Feb 19 NR7 Range Contraction 0.00%
Feb 19 Wide Bands Range Expansion 0.00%
Feb 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.59%
Feb 15 Doji - Bearish? Reversal 1.59%
Feb 15 Wide Bands Range Expansion 1.59%
Feb 15 Oversold Stochastic Weakness 1.59%
Feb 14 Stochastic Buy Signal Bullish 1.01%
Feb 14 Wide Bands Range Expansion 1.01%

Older signals for ALNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria
Is ALNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.56
52 Week Low 4.8
Average Volume 33,018
200-Day Moving Average 10.4015
50-Day Moving Average 7.2556
20-Day Moving Average 7.1955
10-Day Moving Average 6.726
Average True Range 0.6125
ADX 20.26
+DI 15.5496
-DI 19.3242
Chandelier Exit (Long, 3 ATRs ) 7.4025
Chandelier Exit (Short, 3 ATRs ) 8.1575
Upper Bollinger Band 8.3792
Lower Bollinger Band 6.0118
Percent B (%b) 0.43
BandWidth 32.901119
MACD Line -0.2458
MACD Signal Line -0.2294
MACD Histogram -0.0164
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.41
Resistance 3 (R3) 7.42 7.30 7.35
Resistance 2 (R2) 7.30 7.20 7.30 7.32
Resistance 1 (R1) 7.16 7.14 7.23 7.15 7.30
Pivot Point 7.04 7.04 7.08 7.04 7.04
Support 1 (S1) 6.90 6.94 6.97 6.89 6.74
Support 2 (S2) 6.78 6.88 6.78 6.72
Support 3 (S3) 6.64 6.78 6.70
Support 4 (S4) 6.63